http://orcid.org/0000-0002-3159-3545
Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Amanda C. Camargo, Ursula Matte & Mariana R. Botton. (2023) Identification of adverse drug reactions that may be related to pharmacogenetics in a public hospital in the South of Brazil. Expert Opinion on Drug Safety 22:7, pages 621-627.
Read now
Read now
Jan Trøst Jørgensen & Niels Westergaard. (2022) Predictive biomarkers and personalized pharmacotherapy. Expert Review of Molecular Diagnostics 22:10, pages 919-922.
Read now
Read now
Ramón Cacabelos. (2022) What have we learnt from past failures in Alzheimer’s disease drug discovery?. Expert Opinion on Drug Discovery 17:4, pages 309-323.
Read now
Read now
Denise Türk, Laura Maria Fuhr, Fatima Zahra Marok, Simeon Rüdesheim, Anna Kühn, Dominik Selzer, Matthias Schwab & Thorsten Lehr. (2021) Novel models for the prediction of drug–gene interactions. Expert Opinion on Drug Metabolism & Toxicology 17:11, pages 1293-1310.
Read now
Read now
Ramón Cacabelos. (2020) Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opinion on Drug Metabolism & Toxicology 16:8, pages 673-701.
Read now
Read now
Ramon Cacabelos. (2020) Pharmacogenomics of drugs used to treat brain disorders. Expert Review of Precision Medicine and Drug Development 5:3, pages 181-234.
Read now
Read now
Ramón Cacabelos. (2020) How plausible is an Alzheimer’s disease vaccine?. Expert Opinion on Drug Discovery 15:1, pages 1-6.
Read now
Read now
Articles from other publishers (51)
Alekha K. Dash, Babu Medi, Behnaz Sarrami, Mandana Hasanzad, Somnath Singh & Surabhi Shukla. 2024. Pharmaceutics. Pharmaceutics
437
469
.
Mandana Hasanzad, Negar Sarhangi, Hamid Reza Aghaei Meybodi & Shekoufeh Nikfar. 2024. Encyclopedia of Toxicology. Encyclopedia of Toxicology
467
491
.
Carlo Maria Bellanca, Egle Augello, Anna Flavia Cantone, Rosaria Di Mauro, Giuseppe Antonino Attaguile, Vincenza Di Giovanni, Guido Attilio Condorelli, Giulia Di Benedetto, Giuseppina Cantarella & Renato Bernardini. (2023) Insight into Risk Factors, Pharmacogenetics/Genomics, and Management of Adverse Drug Reactions in Elderly: A Narrative Review. Pharmaceuticals 16:11, pages 1542.
Crossref
Crossref
Romany H. Thabet, Bayan Osama Shehadeh Alshar, Doaa Habes Saleh Alabdallah, Nour Alhuda Zaid Ahmad Alhmoud, Sondos Taher Abdalsalam Alslameen & Youssef Romany Helmy Thabet. (2023) Structure–activity relationships and interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm. Journal of International Medical Research 51:11.
Crossref
Crossref
Junning Feng, Yong Liang & Tianwei Yu. (2023) MM-GANN-DDI: Multimodal Graph-Agnostic Neural Networks for Predicting Drug–Drug Interaction Events. Computers in Biology and Medicine 166, pages 107492.
Crossref
Crossref
Olaia Martínez-Iglesias, Vinogran Naidoo, Iván Carrera, Juan Carlos Carril, Natalia Cacabelos & Ramón Cacabelos. (2023) Influence of Metabolic, Transporter, and Pathogenic Genes on Pharmacogenetics and DNA Methylation in Neurological Disorders. Biology 12:9, pages 1156.
Crossref
Crossref
Wolfgang Sadee, Danxin Wang, Katherine Hartmann & Amanda Ewart Toland. (2023) Pharmacogenomics: Driving Personalized Medicine. Pharmacological Reviews 75:4, pages 789-814.
Crossref
Crossref
Saba Maghari, Tyler Gallo, Salvador Rivas, Alexander German, Minh Q Nguyen Le, Hamed Abbaszadegan, Mark A Zubriski, Craig W Heise & Noel D Landas. (2023) Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients. Pharmacogenomics 24:9, pages 501-508.
Crossref
Crossref
Wenqian Zhou, Jinping Guo, Yujie Li, Xiaoya Ma, Shuangyu Yang, Jie Wei, Huan Zhang, Shanshan Zhang & Tianbo Jin. (2023) Genetic polymorphisms of pharmacogenomic VIP variants in the Hui population from Ningxia Province of China. Functional & Integrative Genomics 23:2.
Crossref
Crossref
Sumudu Rangika Samarasinghe, Wendy Hoy, Sudhir Jadhao, Brendan J. McMorran, Henk-Jan Guchelaar & Shivashankar H. Nagaraj. (2023) The pharmacogenomic landscape of an Indigenous Australian population. Frontiers in Pharmacology 14.
Crossref
Crossref
Vaishnavi Survase, Jasmin Shimpi, Tanvi Sasawade, Shubham Tripathi, MADHUR KULKARNI, POOJA S JANARDAN & TANAJI METHRE. (2023) IDENTIFICATION AND REPORTING OF ADVERSE DRUG REACTIONS IN THE PHARMACOVIGILANCE CENTER OF A TERTIARY CARE HOSPITAL. Asian Journal of Pharmaceutical and Clinical Research, pages 197-200.
Crossref
Crossref
Keren J. Carss, Aimee M. Deaton, Alberto Del Rio-Espinola, Dorothée Diogo, Mark Fielden, Diptee A. Kulkarni, Jonathan Moggs, Peter Newham, Matthew R. Nelson, Frank D. Sistare, Lucas D. Ward & Jing Yuan. (2022) Using human genetics to improve safety assessment of therapeutics. Nature Reviews Drug Discovery 22:2, pages 145-162.
Crossref
Crossref
Savanna San Filippo, Marshall Yuan, Edward Gu, Sabiyah Siddiqui & Savan Patel. (2023) Utilization of Drug Decision Support Strategies Including Drug Characteristics to Reduce the Risk of Iatrogenesis in Advanced Age. Current Pharmacology Reports 9:1, pages 32-42.
Crossref
Crossref
Ramón Cacabelos, Juan C Carril, Lola Corzo, Rocío Pego, Natalia Cacabelos, Margarita Alcaraz, Adriana Muñiz, Olaia Martínez-Iglesias & Vinogran Naidoo. (2023) Pharmacogenetics of anxiety and depression in Alzheimer's disease. Pharmacogenomics 24:1, pages 27-57.
Crossref
Crossref
Jacob Peedicayil. 2023. Handbook of Epigenetics. Handbook of Epigenetics
687
694
.
Michael Schlander, Ramon Schäfer & Lorenz SelbergMichael Schlander, Ramon Schäfer & Lorenz Selberg. 2023. Nutzen der Labormedizin in der Schweiz. Nutzen der Labormedizin in der Schweiz
181
231
.
Seul Lee & Hyung-Keun You. (2022) The etiology and possible molecular mechanisms underlying calcium channel blocker-induced gingival enlargement: a narrative review. Oral Biology Research 46:4, pages 183-188.
Crossref
Crossref
Tong Jia, Caiying Wu, Xiaowen Hu, Sicong Li, Xinyi Zhang, Yuchun Cai, Jing Chen, Luwen Shi, Christine Y. Lu & Xiaoyan Nie. (2022) Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China. Journal of Personalized Medicine 12:12, pages 2021.
Crossref
Crossref
Maren S. FragalaJeffrey A. ShamanRaymond A. LorenzSteven E. Goldberg. (2022) Role of Pharmacogenomics in Comprehensive Medication Management: Considerations for Employers. Population Health Management 25:6, pages 753-762.
Crossref
Crossref
Leonie M. Hitchman, Allamanda Faatoese, Tony R. Merriman, Allison L. Miller, Yusmiati Liau, Oscar E. E. Graham, Ping Siu Kee, John F. Pearson, Tony Fakahau, Vicky A. Cameron, Martin A. Kennedy & Simran D. S. Maggo. (2022) Allelic diversity of the pharmacogene CYP2D6 in New Zealand Māori and Pacific peoples. Frontiers in Genetics 13.
Crossref
Crossref
Youssef Daali. (2022) Personalized Medicine: Pharmacokinetics. Journal of Personalized Medicine 12:10, pages 1660.
Crossref
Crossref
Chao Fang, Wen Ouyang, Youjie Zeng, Qi Pei, Yuhao Xia, Siwan Luo & Minghua Chen. (2022) CYP2A6 and GABRA2 Gene Polymorphisms are Associated With Dexmedetomidine Drug Response. Frontiers in Pharmacology 13.
Crossref
Crossref
Juliana Carla Gomes Rodrigues, Marianne Rodrigues Fernandes, André Maurício Ribeiro-dos-Santos, Gilderlanio Santana de Araújo, Sandro José de Souza, João Farias Guerreiro, Ândrea Ribeiro-dos-Santos, Paulo Pimentel de Assumpção, Ney Pereira Carneiro dos Santos & Sidney Santos. (2022) Pharmacogenomic Profile of Amazonian Amerindians. Journal of Personalized Medicine 12:6, pages 952.
Crossref
Crossref
Ramón Cacabelos. (2022) Pharmacogenetics for Improving Efficacy and Safety in Drug Development
and for Reducing Costs in Alzheimer’s Disease. Current Pharmacogenomics and Personalized Medicine 19:1, pages 3-6.
Crossref
Crossref
Ramon Cacabelos. 2022. Alzheimer's Disease Drug Development. Alzheimer's Disease Drug Development
404
417
.
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, Lola Corzo, Natalia Cacabelos, Rocío Pego & Juan C. Carril. (2022) Personalized Management and Treatment of Alzheimer’s Disease. Life 12:3, pages 460.
Crossref
Crossref
April Prather, Aissa Aifaoui & Jeffrey A Shaman. (2022) Idiopathic Symptoms Resolved by Pharmacogenomics-Enriched Comprehensive Medication Management: A Case Report. Cureus.
Crossref
Crossref
Bei Wang, Jun-Zhu Chen, Xue-Qun Luo, Guo-Hui Wan, Yan-Lai Tang & Qiao-Ping Wang. (2022) The application of genome-wide CRISPR-Cas9 screens to dissect the molecular mechanisms of toxins. Computational and Structural Biotechnology Journal 20, pages 5076-5084.
Crossref
Crossref
Vinogran Naidoo, Olaia Martínez-Iglesias & Ramón Cacabelos. 2022. Epigenetics of Stress and Stress Disorders. Epigenetics of Stress and Stress Disorders
317
392
.
Mandana Hasanzad, Negar Sarhangi, Leila Hashemian & Behnaz Sarrami. 2022. Precision Medicine in Clinical Practice. Precision Medicine in Clinical Practice
13
32
.
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, Lola Corzo, Natalia Cacabelos, Rocío Pego & Juan C. Carril. 2022. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
275
387
.
Ramón Cacabelos, Vinogran Naidoo, Lola Corzo, Natalia Cacabelos & Juan C. Carril. (2021) Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. International Journal of Molecular Sciences 22:24, pages 13302.
Crossref
Crossref
Noah E. Berlow. (2021) Probabilistic Boolean Modeling of Pre‐clinical Tumor Models for Biomarker Identification in Cancer Drug Development. Current Protocols 1:10.
Crossref
Crossref
Niels Westergaard, Lise Tarnow & Charlotte Vermehren. (2021) Comparison of Multidrug Use in the General Population and among Persons with Diabetes in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines. Pharmaceuticals 14:9, pages 899.
Crossref
Crossref
Ramón Cacabelos, Iván Carrera, Olaia Martínez, Ramón Alejo, Lucía Fernández‐Novoa, Pablo Cacabelos, Lola Corzo, Susana Rodríguez, Margarita Alcaraz, Laura Nebril, Iván Tellado, Natalia Cacabelos, Rocío Pego, Vinogran Naidoo & Juan C. Carril. (2021) Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. Medicinal Research Reviews 41:5, pages 2841-2886.
Crossref
Crossref
C. Jeiziner, K. Suter, U. Wernli, J. M. Barbarino, L. Gong, M. Whirl-Carrillo, T. E. Klein, T. D. Szucs, K. E. Hersberger & H. E. Meyer zu Schwabedissen. (2020) Pharmacogenetic information in Swiss drug labels – a systematic analysis. The Pharmacogenomics Journal 21:4, pages 423-434.
Crossref
Crossref
Ramón Cacabelos, Iván Carrera, Olaia Martínez, Vinogran Naidoo, Natalia Cacabelos, Gjumrakch Aliev & Juan C. Carril. (2021) Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson's disease. Drug Development Research 82:5, pages 695-706.
Crossref
Crossref
Ahmad M. Zidan, Eman A. Saad, Nasser E. Ibrahim, Medhat H. Hashem, Amal Mahmoud & Alaa A. Hemeida. (2021) Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection. Heliyon 7:5, pages e06908.
Crossref
Crossref
Ramón Cacabelos, Juan Carril, Lola Corzo, Lucía Fernández-Novoa, Rocío Pego, Natalia Cacabelos, Pablo Cacabelos, Margarita Alcaraz, Iván Tellado & Vinogran Naidoo. (2021) Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer’s Disease. Pharmaceuticals 14:4, pages 366.
Crossref
Crossref
Jeeyun A. Kim, Rachel Ceccarelli & Christine Y. Lu. (2021) Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020). Journal of Personalized Medicine 11:3, pages 179.
Crossref
Crossref
Kristina A. Malsagova, Tatyana V. Butkova, Arthur T. Kopylov, Alexander A. Izotov, Natalia V. Potoldykova, Dmitry V. Enikeev, Vagarshak Grigoryan, Alexander Tarasov, Alexander A. Stepanov & Anna L. Kaysheva. (2020) Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization. Pharmaceutics 12:12, pages 1240.
Crossref
Crossref
Bryan Dafniet, Natacha Cerisier, Karine Audouze & Olivier Taboureau. (2020) Drug‐target‐ADR Network and Possible Implications of Structural Variants in Adverse Events. Molecular Informatics 39:12.
Crossref
Crossref
Zeyun Zhou & Kyle Emerson Hultgren. (2020) Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis. JMIR Public Health and Surveillance 6:3, pages e19266.
Crossref
Crossref
Roy H. Perlis, Daniel Dowd, Maurizio Fava, Todd Lencz & David S. Krause. (2020) Randomized, controlled, participant‐ and rater‐blind trial of pharmacogenomic test‐guided treatment versus treatment as usual for major depressive disorder. Depression and Anxiety 37:9, pages 834-841.
Crossref
Crossref
Rita Romskaug, Torgeir Bruun Wyller, Jørund Straand, Hege Kersten & Espen Molden. (2020) Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy. Drugs & Aging 37:6, pages 425-433.
Crossref
Crossref
Ramon Cacabelos. (2020) Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia. International Journal of Molecular Sciences 21:9, pages 3059.
Crossref
Crossref
Niels Westergaard, Regitze Søgaard Nielsen, Steffen Jørgensen & Charlotte Vermehren. (2020) Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients. Journal of Personalized Medicine 10:1, pages 3.
Crossref
Crossref
Olaia Martínez-Iglesias & Ramon Cacabelos. 2020. Histone Modifications in Therapy. Histone Modifications in Therapy
311
335
.
Prabin Upadhyaya, Alessandra Di Serafino, Luca Sorino, Patrizia Ballerini, Marco Marchisio, Laura Pierdomenico, Liborio Stuppia & Ivana Antonucci. (2019) Genetic and epigenetic modifications induced by chemotherapeutic drugs: human amniotic fluid stem cells as an in-vitro model. BMC Medical Genomics 12:1.
Crossref
Crossref
Simran D.S. Maggo, Kyra L.V. Sycamore, Allison L. Miller & Martin A. Kennedy. (2019) The Three Ps: Psychiatry, Pharmacy, and Pharmacogenomics, a Brief Report From New Zealand. Frontiers in Psychiatry 10.
Crossref
Crossref
Tracy A. O’Mara, Jyotsna Batra & Dylan Glubb. (2019) Editorial: Establishing Genetic Pleiotropy to Identify Common Pharmacological Agents for Common Diseases. Frontiers in Pharmacology 10.
Crossref
Crossref